{"pmid":32386570,"title":"Assessment of SARS-CoV-2 replication in the context of other respiratory viruses.","text":["Assessment of SARS-CoV-2 replication in the context of other respiratory viruses.","Lancet Respir Med","Belser, Jessica A","32386570"],"journal":"Lancet Respir Med","authors":["Belser, Jessica A"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32386570","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/S2213-2600(20)30227-7","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666428892626288641,"score":9.490897,"similar":[{"pmid":32434888,"title":"Replication of SARS-CoV-2 in human respiratory epithelium.","text":["Replication of SARS-CoV-2 in human respiratory epithelium.","Currently, there are four seasonal coronaviruses associated with relatively mild respiratory tract disease in humans. However, there are also a plethora of animal coronaviruses, which have the potential to cross the species border. This regularly results in the emergence of new viruses in humans. In 2002 SARS-CoV emerged, to rapidly disappear in May 2003. In 2012 MERS-CoV was identified as a possible threat to humans, but its pandemic potential so far is minimal, as the human-to-human transmission is ineffective. The end of 2019 brought us information about the SARS-CoV-2 emergence, and the virus rapidly spread in 2020 causing an unprecedented pandemic.At present, the studies on the virus are carried out using a surrogate system based on the immortalized simian Vero E6 cell line. This model is convenient for diagnostics, but it has serious limitations and does not allow for the understanding of virus biology and evolution.Here we show that fully differentiated human airway epithelium cultures constitute an excellent model to study the infection with the novel human coronavirus SARS-CoV-2. We observed an efficient replication of the virus in the tissue, with the maximal replication at 2 days post-infection. The virus replicated in ciliated cells and was released apically.IMPORTANCE SARS-CoV-2 emerged by the end of 2019 to rapidly spread in 2020. At present, it is of utmost importance to understand the virus biology and to rapidly assess the potential of existing drugs and develop new active compounds. While some animal models for such studies are under development, most of the research is carried out in the Vero E6 cells. Here, we propose fully differentiated human airway epithelium cultures as a model for studies on the SARS-CoV-2.","J Virol","Milewska, Aleksandra","Kula-Pacurar, Anna","Wadas, Jakub","Suder, Agnieszka","Szczepanski, Artur","Dabrowska, Agnieszka","Owczarek, Katarzyna","Marcello, Alessandro","Ochman, Marek","Stacel, Tomasz","Rajfur, Zenon","Sanak, Marek","Labaj, Pawel","Branicki, Wojciech","Pyrc, Krzysztof","32434888"],"abstract":["Currently, there are four seasonal coronaviruses associated with relatively mild respiratory tract disease in humans. However, there are also a plethora of animal coronaviruses, which have the potential to cross the species border. This regularly results in the emergence of new viruses in humans. In 2002 SARS-CoV emerged, to rapidly disappear in May 2003. In 2012 MERS-CoV was identified as a possible threat to humans, but its pandemic potential so far is minimal, as the human-to-human transmission is ineffective. The end of 2019 brought us information about the SARS-CoV-2 emergence, and the virus rapidly spread in 2020 causing an unprecedented pandemic.At present, the studies on the virus are carried out using a surrogate system based on the immortalized simian Vero E6 cell line. This model is convenient for diagnostics, but it has serious limitations and does not allow for the understanding of virus biology and evolution.Here we show that fully differentiated human airway epithelium cultures constitute an excellent model to study the infection with the novel human coronavirus SARS-CoV-2. We observed an efficient replication of the virus in the tissue, with the maximal replication at 2 days post-infection. The virus replicated in ciliated cells and was released apically.IMPORTANCE SARS-CoV-2 emerged by the end of 2019 to rapidly spread in 2020. At present, it is of utmost importance to understand the virus biology and to rapidly assess the potential of existing drugs and develop new active compounds. While some animal models for such studies are under development, most of the research is carried out in the Vero E6 cells. Here, we propose fully differentiated human airway epithelium cultures as a model for studies on the SARS-CoV-2."],"journal":"J Virol","authors":["Milewska, Aleksandra","Kula-Pacurar, Anna","Wadas, Jakub","Suder, Agnieszka","Szczepanski, Artur","Dabrowska, Agnieszka","Owczarek, Katarzyna","Marcello, Alessandro","Ochman, Marek","Stacel, Tomasz","Rajfur, Zenon","Sanak, Marek","Labaj, Pawel","Branicki, Wojciech","Pyrc, Krzysztof"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434888","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1128/JVI.00957-20","topics":["Mechanism"],"weight":1,"_version_":1667521393783209984,"score":46.180744},{"pmid":32438371,"title":"Structure of replicating SARS-CoV-2 polymerase.","text":["Structure of replicating SARS-CoV-2 polymerase.","The coronavirus SARS-CoV-2 uses an RNA-dependent RNA polymerase (RdRp) for the replication of its genome and the transcription of its genes(1-3). Here we present the cryo-electron microscopic structure of the SARS-CoV-2 RdRp in active form, mimicking the replicating enzyme. The structure comprises the viral proteins nsp12, nsp8, and nsp7, and over two turns of RNA template-product duplex. The active site cleft of nsp12 binds the first turn of RNA and mediates RdRp activity with conserved residues. Two copies of nsp8 bind to opposite sides of the cleft and position the second turn of RNA. Long helical extensions in nsp8 protrude along exiting RNA, forming positively charged 'sliding poles'. These sliding poles can account for the known processivity of the RdRp that is required for replicating the long coronavirus genome(3). Our results enable a detailed analysis of the inhibitory mechanisms that underlie the antiviral activity of substances such as remdesivir, a drug for the treatment of coronavirus disease 2019 (COVID-19)(4).","Nature","Hillen, Hauke S","Kokic, Goran","Farnung, Lucas","Dienemann, Christian","Tegunov, Dimitry","Cramer, Patrick","32438371"],"abstract":["The coronavirus SARS-CoV-2 uses an RNA-dependent RNA polymerase (RdRp) for the replication of its genome and the transcription of its genes(1-3). Here we present the cryo-electron microscopic structure of the SARS-CoV-2 RdRp in active form, mimicking the replicating enzyme. The structure comprises the viral proteins nsp12, nsp8, and nsp7, and over two turns of RNA template-product duplex. The active site cleft of nsp12 binds the first turn of RNA and mediates RdRp activity with conserved residues. Two copies of nsp8 bind to opposite sides of the cleft and position the second turn of RNA. Long helical extensions in nsp8 protrude along exiting RNA, forming positively charged 'sliding poles'. These sliding poles can account for the known processivity of the RdRp that is required for replicating the long coronavirus genome(3). Our results enable a detailed analysis of the inhibitory mechanisms that underlie the antiviral activity of substances such as remdesivir, a drug for the treatment of coronavirus disease 2019 (COVID-19)(4)."],"journal":"Nature","authors":["Hillen, Hauke S","Kokic, Goran","Farnung, Lucas","Dienemann, Christian","Tegunov, Dimitry","Cramer, Patrick"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32438371","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41586-020-2368-8","e_drugs":["remdesivir"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667521393648992256,"score":45.93842},{"pmid":32502901,"title":"Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.","text":["Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.","Coronavirus disease (COVID-19) is caused by SARS-COV2 and has resulted in more than four million cases globally and the death cases exceeded 300,000. Normally, a range of surviving and propagating host factors must be employed for the completion of the infectious process including RPs. Viral protein biosynthesis involves the interaction of numerous RPs with viral mRNA, proteins which are necessary for viruses replication regulation and infection inside the host cells. Most of these interactions are crucial for virus activation and accumulation. However, only small percentage of these proteins is specifically responsible for host cells protection by triggering the immune pathway against virus. This research proposes RPs extracted from bacillus sp. and yeast as new forum for the advancement of antiviral therapy. Hitherto, antiviral therapy with RPs-involving viral infection has not been widely investigated as critical targets. Also, exploring antiviral strategy based on RPs could be a promising guide for more potential therapeutics.","Med Hypotheses","Rofeal, Marian","El-Malek, Fady Abd","32502901"],"abstract":["Coronavirus disease (COVID-19) is caused by SARS-COV2 and has resulted in more than four million cases globally and the death cases exceeded 300,000. Normally, a range of surviving and propagating host factors must be employed for the completion of the infectious process including RPs. Viral protein biosynthesis involves the interaction of numerous RPs with viral mRNA, proteins which are necessary for viruses replication regulation and infection inside the host cells. Most of these interactions are crucial for virus activation and accumulation. However, only small percentage of these proteins is specifically responsible for host cells protection by triggering the immune pathway against virus. This research proposes RPs extracted from bacillus sp. and yeast as new forum for the advancement of antiviral therapy. Hitherto, antiviral therapy with RPs-involving viral infection has not been widely investigated as critical targets. Also, exploring antiviral strategy based on RPs could be a promising guide for more potential therapeutics."],"journal":"Med Hypotheses","authors":["Rofeal, Marian","El-Malek, Fady Abd"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502901","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.mehy.2020.109904","keywords":["antiviral","coronavirus","ribosomal proteins","sars-cov 2","viral translation"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668804508761718784,"score":42.14712},{"pmid":32251768,"pmcid":"PMC7129059","title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.","text":["The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.","Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.","Antiviral Res","Caly, Leon","Druce, Julian D","Catton, Mike G","Jans, David A","Wagstaff, Kylie M","32251768"],"abstract":["Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans."],"journal":"Antiviral Res","authors":["Caly, Leon","Druce, Julian D","Catton, Mike G","Jans, David A","Wagstaff, Kylie M"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251768","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.antiviral.2020.104787","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490965852160,"score":40.33275},{"pmid":32251767,"pmcid":"PMC7127386","title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.","text":["Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.","An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 muM, 26.63 muM, 2.55 muM and 0.46 muM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 muM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 muM in combination with emetine at 0.195 muM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.","Antiviral Res","Choy, Ka-Tim","Wong, Alvina Yin-Lam","Kaewpreedee, Prathanporn","Sia, Sin Fun","Chen, Dongdong","Hui, Kenrie Pui Yan","Chu, Daniel Ka Wing","Chan, Michael Chi Wai","Cheung, Peter Pak-Hang","Huang, Xuhui","Peiris, Malik","Yen, Hui-Ling","32251767"],"abstract":["An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 muM, 26.63 muM, 2.55 muM and 0.46 muM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 muM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 muM in combination with emetine at 0.195 muM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits."],"journal":"Antiviral Res","authors":["Choy, Ka-Tim","Wong, Alvina Yin-Lam","Kaewpreedee, Prathanporn","Sia, Sin Fun","Chen, Dongdong","Hui, Kenrie Pui Yan","Chu, Daniel Ka Wing","Chan, Michael Chi Wai","Cheung, Peter Pak-Hang","Huang, Xuhui","Peiris, Malik","Yen, Hui-Ling"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251767","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.antiviral.2020.104786","keywords":["abstract","covid-19","emetine","homoharringtonine","lopinavir","remdesivir","ritonavir"],"e_drugs":["remdesivir","Ribavirin","Lopinavir","Emetine","favipiravir","Homoharringtonine"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490993115138,"score":40.33275}]}